EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-TBI-02(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under directives from the ICMR and the National Medical Commission (NMC), stem cell therapy for TBI is strictly investigational and experimental. It is not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure and does not replace emergency craniotomy, intracranial pressure (ICP) management, or continuous neuro-rehabilitation.
Pathophysiology & Disease Context:
Traumatic Brain Injury (TBI) results from mechanical impacts (falls, motor vehicle collisions, sports injuries) triggering primary mechanical tissue contusion followed by secondary cascades: neuro-inflammation, blood-brain barrier disruption, microglial activation, and diffuse axonal injury (DAI).
Biological Rationale & Paracrine Action:
Explores targeted administration of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to release neurotrophic and pro-angiogenic factors (BDNF, GDNF, VEGF), dampen chronic microglial neuro-inflammation, stabilize the blood-brain barrier, and support endogenous synaptic plasticity.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Medically stable individuals in the subacute or chronic phase ($>3\text{ to }6$ months post-injury) presenting with non-progressive motor deficits, cognitive impairment, spasticity, or ataxia who have reached a functional recovery plateau despite compliant rehabilitation.
Mandatory Pre-Procedure Diagnostics:
High-resolution Brain 3T MRI (including Diffusion Tensor Imaging [DTI], SWI for traumatic microbleeds, and FLAIR for encephalomalacia/contusions), baseline electroencephalogram (EEG) to assess subclinical epileptiform activity, Glasgow Outcome Scale-Extended (GOS-E), Functional Independence Measure (FIM), and standard metabolic panels.
Strict Safety Exclusion Parameters:
Acute, unstable neurotrauma ($<1\text{ to }3$ months post-injury); active intracranial hemorrhage, hydrocephalus, or elevated intracranial pressure requiring surgical shunting/decompression; uncontrolled refractory post-traumatic epilepsy; severe systemic infections; or active malignancies.
Triage Protocol & Multi-Specialty Clearance:
Multidisciplinary panel review by a neurosurgeon, neurologist, and physical medicine specialist prior to issuing international travel approval.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Motor Coordination & Gait: Modest gains in balance, reduction in post-traumatic ataxia, and improved assisted walking velocity.
- Spasticity & Tone Modulation: Downregulation of limb hypertonia and involuntary muscle resistance on the Modified Ashworth Scale (MAS).
- Cognitive Processing & Focus: Subtle improvements in attention span, memory recall, and speed of processing on structured neuropsychological tracking.
- Speech & Executive Function: Enhanced oral-motor articulation, reduction in dysarthria, and better self-regulation in daily planning.
- Daily Independence (ADLs): Incremental improvements in self-care, feeding, and personal autonomy (reflected on FIM and Barthel Index scales).
Documented Procedural Risks & Limits:
- Self-limiting low-grade fever, headache, lightheadedness, or localized procedural soreness resolving within 24–48 hours.
- Rare risks: transient seizure threshold alteration (monitored closely with anti-epileptic maintenance) or transient meningismus following intrathecal administration.
- No Guaranteed Brain Tissue Regeneration: Cellular therapy cannot regenerate cavity-like necrotic encephalomalacia or completely replace destroyed neuronal architecture; functional improvements require sustained neuroplastic training.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Infrastructure
Procedures performed in tertiary neuroscience hospitals accredited by NABH and JCI with dedicated neuro-intensive care units.
Specialized Neuro-Faculty
Jointly supervised by board-certified neurosurgeons, cognitive neurologists, and certified neuro-rehabilitation therapists.
cGMP Cleanroom Purity
Cell isolation conforms strictly to international Good Manufacturing Practices and Indian CDSCO quality standards.
Ethics Oversight
Supervised by active Institutional Ethics Committees (IEC) registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with senior neurosurgeons to evaluate 3T MRI/DTI scans, GOS-E status, and establish realistic functional goals.
Government Medical Visa
Priority assistance with official Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport reception, priority clinical appointments, and medical documentation.
Structured Long-Term Follow-Up
Telehealth reviews at Months 1, 3, 6, and 12, coordinating repeat cognitive/motor scale evaluations with your home medical team.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Wheelchair-Accessible Transfers
Private, air-conditioned vehicle pick-up and drop-off accommodating wheelchairs, walkers, and support gear for comfortable, low-stress transit.
Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the medical campus, featuring wide doorways, step-free access, elevator facilities, and roll-in showers with grab rails.
Patient Amenities
Dysphagia-safe and brain-supportive nutritional meal options supervised by clinical dietitians, local SIM registration, wheelchair/walker loaners, and 24/7 on-call nursing support.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Traumatic Brain Injury (TBI)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Pivotal Phase 2 Double-Blind, Sham-Controlled Trial of Modified Allogeneic MSCs in Chronic TBI (STEMTRA Trial)
Kawabori, M., Weintraub, A. H., Imai, H., Zinkevych, Y., McAllister, P., Steinberg, G. K., Fraczkowski, D., Gans, B. M., Carter, D. A., Okonkwo, D. O., & STEMTRA Trial Collaborators. (2021). Cell Therapy for Chronic TBI: Interim Analysis of the Randomized Controlled STEMTRA Trial. Neurology, 96(8), e1202–e1214. Clinical Trial Registry Reference: NCT02416492 on ClinicalTrials.gov
Randomized Controlled Trial of Umbilical Cord Mesenchymal Stem Cells in Chronic TBI Sequelae
Wang, S., Cheng, H., Dai, G., Wang, X., Hua, R., Liu, X., Wang, P., Chen, K., & An, Y. (2013). Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. Brain Research, 1532, 76–84.
Phase 1 Clinical Trial of Intravenous Autologous Bone Marrow Mononuclear Progenitors in Severe TBI
Cox, C. S. Jr., Baumgartner, J. E., Harting, M. T., Worth, L. L., Walker, P. A., Hassan, A., Day, M. C., Shah, S., Sumien, N., & Savitz, S. I. (2011). Autologous bone marrow mononuclear cells reduce therapeutic intensity for severe traumatic brain injury in children. Pediatric Critical Care Medicine, 12(6), e345–e352. / Cox, C. S. Jr., et al. (2017). Phase I/II study of autologous bone marrow mononuclear cells in pediatric severe traumatic brain injury. Neurosurgery, 79(6), 720–729.
Adaptive Phase 2 Randomized Trial of Intravenous MSCs for Severe Acute TBI (MATRIx Study)
Zanier, E. R., Pischiutta, F., Riganti, L., et al. (2023). MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a multicenter, randomized, double-blind, placebo-controlled, adaptive phase II dose-finding study. Trials, 24(1), 546.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell and biological therapies for Traumatic Brain Injury (TBI) are classified as strictly investigational and experimental. They are not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. Cellular therapies do not replace primary neurosurgical management, seizure prevention protocols, or essential long-term physical, occupational, and speech rehabilitation. Patients must continue all prescribed neuro-protective medications under specialist supervision.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.